Ro Online GLP-1 Clinic Review
US$ 23.44
fda approves first oral glp-1 obesity drug august 1 2025 for Weight Management Novo Nordisk's weight-loss pill wins
Description
Lorcaserin, 25%
2024 Jul 17;10(1):77
The misuse of GLP-1 drugs without clinical oversight can lead to severe health complications. Also Read: Generic Semaglutide launches in India after patent expiry Side effects range from mild to severe Common side effects include nausea, vomiting, diarrhea, constipation, and loss of appetite
In a Phase 3 trial, orforglipron demonstrated a reduction in HbA1c levels by up to 1.6% and an average weight loss of 16 pounds over 40 weeks
These results indicated that GLP-1RAs might play a useful role in the future treatment of PD
GLP-1RAs suppress NLRP3 inflammasome activation via attenuating the expression of NLRP3, apoptotic speck containing protein (ASC), and cleaves caspase 1 (p10) [111]
